A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects

NCT03242239 | Completed Phase 1

• 1 other identifier: ALT02
• Study Type: interventional
• Target: 105
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to compare ALT02 (Trastuzumab biosimilar) and Herceptin® (US-licensed Trastuzumab and EU-licensed Trastuzumab) in healthy male subjects about the pharmacokinetics, safety, tolerability and immunogenicity.

Conditions

Healthy

Keywords

HER2 Positive Breast Cancer; Trastuzumab; Biosimilar

Outcome Measures

Primary Outcomes (1)

• AUC0-inf: area under the concentration-time curve from time zero to infinity

  43 days

Secondary Outcomes (7)

• AUC0-t: area under the concentration-time curve from time zero to the last non-zero concentration

  43 days

• Cmax: maximum observed concentration

  43 days

• Tmax: time of observed Cmax

  43 days

• Kel: apparent terminal elimination rate constant

  43 days

• T½ el: apparent terminal half-life

  43 days

Study Arms (3)

ALT02

EXPERIMENTAL

Biological: ALT02

EU-licensed Herceptin

ACTIVE COMPARATOR

Biological: EU-licensed Herceptin

US-licensed Herceptin

ACTIVE COMPARATOR

Biological: US-licensed Herceptin

Interventions

ALT02 BIOLOGICAL

ALT02

EU-licensed Herceptin BIOLOGICAL

EU-licensed Herceptin

US-licensed Herceptin BIOLOGICAL

US-licensed Herceptin

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male subjects
• Have a body weight over 50.0 kg and a body mass index over than 18.5 and less than 30.0 kg/m², inclusive.

You may not qualify if:

• Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
• Positive urine drug screen or alcohol breath test at screening.
• History of allergic reactions to trastuzumab, benzyl alcohol, murine proteins, or other related drugs.
• Any reason which, in the opinion of the Qualified Investigator, would prevent the subject from participating in the study.
• Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
• History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week \[1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol\]).
• History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine \[PCP\], and crack) within 1 year prior to screening.
• Use of trastuzumab or another monoclonal antibody for a medical condition or in the context of another clinical trial.
• Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to dosing, administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
• Use of medication other than topical products without significant systemic absorption:
• prescription medication within 14 days prior to dose administration;
• over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);
• a depot injection or an implant of any drug within 3 months prior to dose administration.
• Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to dosing.
• Hemoglobin \<128 g/L and hematocrit \<0.37 L/L at screening.

Sponsors & Collaborators

• Alteogen, Inc.: lead
• Cristália Produtos Químicos Farmacêuticos Ltda.: collaborator

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 2, 2017
• First Posted: August 8, 2017
• Study Start: February 9, 2016
• Primary Completion: August 4, 2016
• Study Completion: September 30, 2016
• Last Updated: August 21, 2017

Record last verified: 2017-08